AstraZeneca and Daiichi Sankyo said Monday they received FDA approval for their [fam-] trastuzumab deruxtecan-nxki, which will be marketed as Enhertu. [Fam-] trastuzumab deruxtecan is an antibody–drug conjugate (ADC) designed to delivery cytotoxic chemotherapy to cancer cells via a human epidermal receptor 2 (HER2) antibody attached to a novel topoisomerase I inhibitor payload and a tetrapeptide-based linker.
AstraZeneca and Daiichi Sankyo said Monday they received FDA approval for their [fam-] trastuzumab deruxtecan-nxki, which will be marketed as Enhertu. [Fam-] trastuzumab deruxtecan is an antibody—drug conjugate (ADC) designed to delivery cytotoxic chemotherapy to cancer cells via a human epidermal receptor 2 (HER2) antibody attached to a novel topoisomerase I inhibitor payload and a tetrapeptide-based linker.
The approval is for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2-based regimens.
The company recently presented results from its pivotal phase 2 study, DESTINY-Breast01, at the at the San Antonio Breast Cancer Symposium in San Antonio, Texas and also published in The New England Journal of Medicine.
The companies said in a statement the clearance came under Accelerated Approval based on tumor response rate and duration of response. “Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial,” the companies said.
In DESTINY, 184 female patients with HER2-positive metastatic breast cancer received 5.4 mg/kg of Enhertu as a monotherapy; all patients previously were treated with prior trastuzumab, ado-trastuzumab emtansine, and 66% had prior pertuzumab.
The phase 2 trial results showed a confirmed objective response rate of 60.3% (n = 111; 95% CI, 52.9-67.4), including a 4.3% complete response rate (n = 8) and a 56.0% partial response rate (n = 103). A median duration of response of 14.8 months (95% CI, 13.8-16.9) was demonstrated as of August 1, 2019.
In addition, patients had a median progression-free survival of 16.4 months (95% CI, 12.7-not estimable), based upon a median duration of follow-up of 11.1 months.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.